Teniposide (VM-26) and ara-C in the treatment of adult acute lymphoblastic leukemia.
Linker
C A
CA
Levitt
L J
LJ
O'Donnell
M
M
Ries
C A
CA
Forman
S J
SJ
D000328:Adult; D000954:Antigens, Surface / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D013713:Teniposide / Q000008:administration & dosage* / Q000009:adverse effects; D014750:Vincristine / Q000008:administration & dosage
D000954:Antigens, Surface; D003561:Cytarabine; D014750:Vincristine; D013713:Teniposide; D001215:Asparaginase; D011034:Podophyllotoxin; D011241:Prednisone; D003630:Daunorubicin